Clinical trial NCT00272337 - References

Cardiovascular Diseases — Aspirin Dose and Atherosclerosis in Patients With Heart Disease

Citation(s)

•   Grosser N, Abate A, Oberle S, Vreman HJ, Dennery PA, Becker JC, Pohle T, Seidman DS, Schröder H
  Heme oxygenase-1 induction may explain the antioxidant profile of aspirin. Biochem Biophys Res Commun. 2003 Sep 5;308(4):956-60.
•   Hennekens CH, Buring JE, Sandercock P, Collins R, Peto R
  Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation. 1989 Oct;80(4):749-56. Review.
•   Hennekens CH, Dyken ML, Fuster V
  Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 1997 Oct 21;96(8):2751-3.
•   Hennekens CH, Hollar D, Baigent C
  Sex-related differences in response to aspirin in cardiovascular disease: an untested hypothesis. Nat Clin Pract Cardiovasc Med. 2006 Jan;3(1):4-5.
•   Hennekens CH, Schror K, Weisman S, FitzGerald GA
  Terms and conditions: semantic complexity and aspirin resistance. Circulation. 2004 Sep 21;110(12):1706-8. Review.
•   Ikonomidis I, Andreotti F, Economou E, Stefanadis C, Toutouzas P, Nihoyannopoulos P
  Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation. 1999 Aug 24;100(8):793-8.
•   Mustard JF, Moore S, Packham MA, Kinlough-Rathbone RL
  Platelets, thrombosis and atherosclerosis. Prog Biochem Pharmacol. 1977;13:312-25.
•   Mustard JF, Packham MA, Kinlough-Rathbone RL
  Platelets and thrombosis in the development of atherosclerosis and its complications. Adv Exp Med Biol. 1978;102:7-30. Review.
•   Mustard JF, Packham MA
  The role of blood and platelets in atherosclerosis and the complications of atherosclerosis. Thromb Diath Haemorrh. 1975 Jun 30;33(3):444-56.
•   Oberle S, Polte T, Abate A, Podhaisky HP, Schröder H
  Aspirin increases ferritin synthesis in endothelial cells: a novel antioxidant pathway. Circ Res. 1998 May 18;82(9):1016-20.
•   Patrignani P, Filabozzi P, Patrono C
  Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest. 1982 Jun;69(6):1366-72.
•   Reilly IA, FitzGerald GA
  Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987 Jan;69(1):180-6.
•   Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH
  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997 Apr 3;336(14):973-9. Erratum in: N Engl J Med 1997 Jul 31;337(5):356.
•   Roth GJ, Stanford N, Majerus PW
  Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975 Aug;72(8):3073-6.
•   Steer KA, Wallace TM, Bolton CH, Hartog M
  Aspirin protects low density lipoprotein from oxidative modification. Heart. 1997 Apr;77(4):333-7.
•   Vane JR
  Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971 Jun 23;231(25):232-5.
•   Williams A, Hennekens CH
  The role of aspirin in cardiovascular diseases--forgotten benefits? Expert Opin Pharmacother. 2004 Jan;5(1):109-15. Review.
•   Wu R, Lamontagne D, de Champlain J
  Antioxidative properties of acetylsalicylic Acid on vascular tissues from normotensive and spontaneously hypertensive rats. Circulation. 2002 Jan 22;105(3):387-92.

A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation & Endothelial Function in Secondary Prevention (Pts w/Chronic Stable Coronary Disease)

Details for clinical trial NCT00272337